Download Sample
Add to CartNeuro Immunoassay Market
By Technology;
Radioimmunoassays (RIA), Polymerase Chain Reaction (PCR), ELISA, Western Blot, Rapid Tests and ELISPOTBy Product;
Reagents & Kits and AnalysersBy Application;
Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, ALS and Spinal Muscular Atrophy (SMA)By End User;
Hospitals, Clinics, Academic Organizations, Biopharmaceutical Companies, Pharmaceutical Companies and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Neuro Immunoassay Market Overview
Neuro Immunoassay Market (USD Million)
Neuro Immunoassay Market was valued at USD 2,881.51 million in the year 2024. The size of this market is expected to increase to USD 4,867.46 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.8%.
Neuro Immunoassay Market
*Market size in USD million
CAGR 7.8 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 7.8 % |
| Market Size (2024) | USD 2,881.51 Million |
| Market Size (2031) | USD 4,867.46 Million |
| Market Concentration | Medium |
| Report Pages | 369 |
Major Players
- Intrinsic LifeSciences
- Danaher Corporation
- Becton Dickinson and Company
- Akers Biosciences, Inc
- Abbott Laboratories
- EDP Biotech Corporation
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Neuro Immunoassay Market
Fragmented - Highly competitive market without dominant players
The Neuro Immunoassay Market is growing notably, with demand rising by over 40% due to an increase in neurodegenerative and autoimmune disorders. Providers are increasingly relying on immunoassay platforms for early disease detection and monitoring. Companies are executing clear strategies to deploy reagent kits and instruments across hospitals and research labs. Strong collaboration between diagnostic innovators and neuroscience centers is supporting sustained market expansion.
Strategic Collaborations Powering Market Access
Over 38% of new assay solutions are introduced via strategic collaborations among biotech firms, diagnostics manufacturers and academic labs. These alliances streamline regulatory pathways and strengthen credibility. Mergers and joint ventures expand distribution channels and broaden access to diagnostic platforms. These collaborative networks underpin consistent market growth.
Wider Adoption Across Clinical and Research Settings
Adoption of neuro immunoassay solutions has increased by more than 42% across hospital labs, clinical trial networks,and pharma development centers. Providers are integrating these assays into screening, monitoring, and research workflows. Companies pursue comprehensive growth strategies like bundled instrument kits, training modules and service contracts. Collaborating with health systems enhances accessibility and supports scalable expansion.
Future Outlook Focused on Smart, Multiplex Platforms
More than 44% of upcoming platforms feature multiplex detection, digital connectivity and real‑time analysis—defining the market’s future outlook. These systems support personalized diagnostics and integration with digital health tools. Ongoing innovation in predictive analytics and cloud reporting, coupled with extensive collaboration, is shaping next‑generation immunoassay solutions and long‑term expansion.
Neuro Immunoassay Market Recent Developments
-
September 2022: the National Institutes of Health (NIH)declared two transformative projects supported by the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative: The BRAIN Initiative Cell Atlas Network (BICAN) and the Armamentarium for Precision Brain Cell Access. These BRAIN 2.0 projects aim to transform the understanding of brain cell types and the precise tools needed to access them, bringing one step closer to unraveling the complex workings of the human brain.
-
July 2022: Labcorp, a leading global life sciences company, announced the launch of the first widely accessible test that provides direct evidence of neurodegeneration and neuronal injury. The new Neurofilament Light Chain (NFL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients
Neuro Immunoassay Segment Analysis
In this report, the Neuro Immunoassay Market has been segmented by Technology, Product, Application, End User and Geography.
Neuro Immunoassay Market, Segmentation by Technology
The Neuro Immunoassay Market has been segmented by Technology into Radioimmunoassays (RIA), Polymerase Chain Reaction (PCR), ELISA, Western Blot, Rapid Tests and ELISPOT.
Radioimmunoassays (RIA)
Radioimmunoassays represent a significant segment of the neuro immunoassay market, contributing about 18% of total usage. Known for their exceptional sensitivity, RIAs are ideal for detecting trace levels of hormones and antigens in neurological diagnostics. This technique continues to be a key tool in both research and clinical applications.
Polymerase Chain Reaction (PCR)
Polymerase Chain Reaction technology holds a strong 25% market share, recognized for its precision and speed in detecting genetic and infectious markers related to neurological disorders. The flexibility of PCR, including quantitative and real-time capabilities, makes it indispensable for both research laboratories and clinical diagnostics.
ELISA
With an impressive 30% share, ELISA remains the leading neuro immunoassay method, valued for its affordability and accurate biomarker quantification. It is widely applied in the detection of autoimmune neurological diseases and in patient monitoring, with high throughput benefits for mass screenings.
Western Blot
Western Blot accounts for about 12% of the market, providing unmatched specificity in protein identification. This technique plays a crucial role in confirmatory testing, particularly for neurological infections such as Lyme disease and remains a standard in many research facilities.
Rapid Tests
Holding a 10% market share, rapid tests are essential for point-of-care neuro diagnostics. Their speed and convenience allow for early detection and timely intervention, especially in emergency and urgent care environments.
ELISPOT
ELISPOT, with a 5% market presence, is a specialized tool in neuroimmunology research. It excels in evaluating cell-mediated immune responses, offering deep insights into immune system activity in neurological diseases.
Neuro Immunoassay Market, Segmentation by Product
The Neuro Immunoassay Market has been segmented by Product into Reagents and Kits,and Analysers.
Reagents
Reagents represent approximately 45% of the neuro immunoassay market, underscoring their importance in delivering accurate and reproducible results. They enhance assay sensitivity and specificity, making them indispensable in both clinical diagnostics and research. Ongoing advancements in reagent formulation continue to boost their effectiveness and market demand.
Kits
Kits account for nearly 40% of market share, widely appreciated for their ease of use and consistent performance. These pre-formulated solutions streamline neuro immunoassay procedures by reducing preparation time and minimizing the risk of errors. Their growing adoption in hospital laboratories and research facilities reflects their reliability and efficiency.
Analysers
Analysers make up about 15% of the market, offering automation and high-throughput testing capabilities. These instruments significantly improve processing speed and accuracy in neuro immunoassay testing, making them essential for large-scale diagnostic operations and advanced research applications.
Neuro Immunoassay Market, Segmentation by Application
The Neuro Immunoassay Market has been segmented by Application into Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, ALS and Spinal Muscular Atrophy (SMA).
Alzheimer’s Disease
Alzheimer’s Disease holds nearly 40% of the neuro immunoassay market share, fueled by the increasing burden of neurodegenerative conditions among aging populations. The use of biomarker-based immunoassays plays a pivotal role in early detection, enabling timely intervention and improved patient outcomes.
Parkinson’s Disease
Parkinson’s Disease represents approximately 25% of the application market, driven by the need for precise identification of disease-specific proteins through immunoassay diagnostics. These tools support early and accurate diagnosis while improving monitoring and treatment strategies.
Huntington’s Disease
Huntington’s Disease makes up around 15% of the market, with neuro immunoassays facilitating the detection of genetic biomarkers and protein biomarkers linked to disease progression. This capability is vital for both research and the development of targeted therapies.
ALS (Amyotrophic Lateral Sclerosis)
ALS comprises about 12% of applications, with immunoassay testing enhancing research into disease mechanisms and supporting therapeutic development. Increased investments in ALS-focused studies are boosting its use in clinical and laboratory environments.
Spinal Muscular Atrophy (SMA)
SMA accounts for roughly 8% of the market, as immunoassays are essential for early genetic screening and tracking treatment effectiveness. Expanding newborn screening programs are further accelerating adoption in this segment.
Neuro Immunoassay Market, Segmentation by End User
The Neuro Immunoassay Market has been segmented by End User into Hospitals, Clinics, Academic Organizations, Biopharmaceutical Companies, Pharmaceutical Companies and Others
Hospitals
Hospitals capture about 35% of the neuro immunoassay market’s end-user segment, benefiting from high patient volumes and well-equipped diagnostic infrastructure. They remain essential for comprehensive neurological testing, treatment monitoring and mass screening initiatives.
Clinics
Clinics account for approximately 20% of demand, providing patients with quick and accessible diagnostic services. The increasing use of neuro immunoassays in these settings is driven by faster results and the growing appeal of outpatient testing facilities.
Academic Organizations
Academic organizations hold nearly 15% of the market, serving as vital centers for research and technology development. They contribute to advancing neuro immunoassay methodologies and discovering new biomarkers for neurological diseases.
Biopharmaceutical Companies
Biopharmaceutical companies represent around 12% of usage, relying on neuro immunoassays to support drug development pipelines. These assays aid in therapeutic target identification, efficacy assessment and preclinical research.
Pharmaceutical Companies
Pharmaceutical companies make up about 10% of the market, utilizing neuro immunoassays in clinical trials, safety assessments and regulatory compliance processes to ensure drug reliability and effectiveness.
Others
Other end-users, comprising around 8% of the market, include diagnostic laboratories, CROs and public health agencies. They apply neuro immunoassays for specialized diagnostic testing, population health studies and targeted screening programs.
Neuro Immunoassay Market, Segmentation by Geography
In this report, the Neuro Immunoassay Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa & Latin America.
Regions and Countries Analyzed in this Report
Neuro Immunoassay Market Share (%), by Geographical Region.
North America
Holding nearly 40% of the neuro immunoassay market, North America remains the dominant region due to its advanced healthcare infrastructure, early adoption of diagnostic innovations and high R&D spending on neurological testing. The region also benefits from strong industry-academia collaborations.
Europe
With approximately 30% market share, Europe benefits from well-established healthcare networks, significant government research funding and a growing patient base for neurological disorders. The emphasis on early detection is driving immunoassay adoption.
Asia Pacific
Representing about 20% of the market, Asia Pacific is witnessing the fastest growth, fueled by expanding healthcare accessibility, rising public awareness and investment in advanced diagnostics. Emerging economies are major contributors to this growth trend.
Middle East and Africa
Accounting for roughly 6% of global share, Middle East and Africa are gradually improving in terms of healthcare facilities and diagnostic capabilities. Increased attention on neurological disease prevention supports steady market expansion.
Latin America
Contributing close to 4% of the market, Latin America is seeing growth from upgraded diagnostic infrastructure, enhanced training of medical professionals and broader adoption of advanced immunoassay techniques for neurological conditions.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Neuro Immunoassay Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers :
- Rising incidence of neurological diseases
- Increasing investment in neuroscience research
-
Technological advancements -The Global Neuro Immunoassay Market has seen significant technological advancements that enhance the accuracy, efficiency and scope of immunoassay applications. Innovations in enzyme immunoassay (EIA), radioimmunoassay (RIA), fluoroimmunoassay (FIA), chemiluminescent immunoassay (CLIA) and counting immunoassay (CIA) have revolutionized the market. These advancements allow for more precise detection of drug levels (such as digoxin and vancomycin), hormone levels (such as insulin, TSH, and estrogen), and cancer markers (like PSA, CA-125, and AFP). The development of the anti-SARS-CoV-2 test, a qualitative serological test that detects total antibody responses (IgM, IgG, and IgA) to expressed SARS-CoV-2 viral antigens in serum or plasma, exemplifies how new technologies can quickly address emerging health challenges.
As these technological improvements have expanded the market's potential by enabling the use of both monoclonal and polyclonal antibodies in immunoassays. Enhanced antibody specificity and affinity have improved the detection and diagnosis of neurological diseases such as Alzheimer's, Parkinson's, Huntington's, ALS and Spinal Muscular Atrophy (SMA). These innovations are crucial for the increasing demand in hospitals, clinics, academic organizations, biopharmaceutical companies, pharmaceutical companies, and other end users. As a result, technological advancements are a driving force behind the market's anticipated growth, offering more reliable and efficient tools for neuroscience research and clinical diagnostics.
Restraints :
- High cost of neuro immunoassays
- Lack of skilled personnel
-
Stringent regulatory requirements - Stringent regulatory requirements play a pivotal role in shaping the landscape of the Global Neuro Immunoassay Market. Regulatory bodies, such as the FDA in the United States and the European Medicines Agency (EMA) in Europe, set standards and guidelines for the development, manufacturing and commercialization of neuro immunoassay products. Compliance with these regulations is essential for ensuring the safety, efficacy, and quality of these diagnostic tools.
Companies operating in the neuro immunoassay market must navigate complex regulatory pathways to obtain approval or clearance for their products. This process involves rigorous testing, documentation and adherence to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). Failure to meet regulatory requirements can result in delays in product launch, increased costs, or even rejection of the product by regulatory authorities, thereby impacting market growth.
The regulatory landscape is continuously evolving, with updates to existing regulations and the introduction of new guidelines. This dynamic environment necessitates ongoing monitoring and adaptation by market players to ensure compliance and maintain market competitiveness. Overall, stringent regulatory requirements are a significant factor influencing the development, commercialization and growth trajectory of the Global Neuro Immunoassay Market.
Opportunities :
- Emerging markets
- Point-of-care testing
-
Companion diagnostics - Companion diagnostics play a crucial role in the Global Neuro Immunoassay Market, offering tailored approaches for patient management and treatment selection. These diagnostics are developed alongside specific therapies, aiding in the identification of patients who are most likely to benefit from particular treatments. In the neurology field, companion diagnostics help in personalizing treatment strategies for conditions like Alzheimer's disease, Parkinson's disease and other neurological disorders. By analyzing biomarkers and genetic markers, companion diagnostics assist clinicians in predicting treatment responses and potential adverse reactions, leading to more effective and safer therapeutic interventions.
As companion diagnostics also facilitate the development and approval of new neurotherapeutics by providing insights into patient stratification and therapy monitoring during clinical trials. As the field of neuroimmunoassays continues to advance, the integration of companion diagnostics holds promise for optimizing patient care and enhancing clinical outcomes in the realm of neurological disorders.
Competitive Landscape Analysis
Key players in Global Neuro Immunoassay Market include,
- Intrinsic LifeSciences
- Danaher Corporation
- Becton Dickinson and Company
- Akers Biosciences, Inc
- Abbott Laboratories
- EDP Biotech Corporation
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By Product
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Neuro Immunoassay Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Rising incidence of neurological diseases
- Increasing investment in neuroscience research
- Technological advancements
- Restraints
- High cost of neuro immunoassays
- Lack of skilled personnel
- Stringent regulatory requirements
- Opportunities
- Emerging markets
- Point-of-care testing
- Companion diagnostics
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
-
Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Neuro Immunoassay Market, By Technology, 2021 - 2031 (USD Million)
- Radioimmunoassays (RIA)
- Polymerase Chain Reaction (PCR)
- ELISA
- Western Blot
- Rapid Tests
- ELISPOT
- Neuro Immunoassay Market, By Product, 2021 - 2031 (USD Million)
- Reagents & Kits
- Analysers
- Neuro Immunoassay Market, By Application, 2021 - 2031 (USD Million)
- Alzheimer’s Disease
- Parkinson’s Disease
- Huntington’s Disease
- ALS
- Spinal Muscular Atrophy (SMA)
- Neuro Immunoassay Market, By End User, 2021 - 2031 (USD Million)
- Hospitals
- Clinics
- Academic Organizations
- Biopharmaceutical Companies
- Pharmaceutical Companies
- Others
- Neuro Immunoassay Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Neuro Immunoassay Market, By Technology, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Intrinsic LifeSciences
- Danaher Corporation
- Becton Dickinson and Company
- Akers Biosciences, Inc
- Abbott Laboratories, Inc
- EDP Biotech Corporation
- Company Profiles
- Analyst Views
- Future Outlook of the Market